Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

Newsfile July 7, 2023

Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering

GlobeNewswire July 6, 2023

Initial Data from Allarity's Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

GlobeNewswire July 5, 2023

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

GlobeNewswire June 28, 2023

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

GlobeNewswire June 27, 2023

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

GlobeNewswire June 20, 2023

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

GlobeNewswire May 30, 2023

Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

ACCESS Newswire April 27, 2023

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

GlobeNewswire April 19, 2023

This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial

ACCESS Newswire April 17, 2023

Abstract Evaluating Allarity's DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

GlobeNewswire April 11, 2023

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

GlobeNewswire March 28, 2023

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

GlobeNewswire March 24, 2023

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

GlobeNewswire March 20, 2023

Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

GlobeNewswire January 20, 2023

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

GlobeNewswire December 1, 2022

Allarity Therapeutics Reports Third Quarter 2022 Financial Results

GlobeNewswire November 15, 2022

Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

GlobeNewswire November 7, 2022

Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

TheNewsWire October 18, 2022

Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements

GlobeNewswire October 11, 2022